6-K filed Sep 8, 2026 at 07:30 ET
BrainsWay announced publication of a pilot study (n=12) in the Journal of Geriatric Psychiatry and Neurology showing Deep TMS achieved an 83.3% response rate and 50% remission rate for depressive symptoms in patients with comorbid MDD and early-stage Alzheimer's disease, alongside measurable neurophysiological changes. This is an early-stage, hypothesis-generating result in a new indication (Alzheimer's) for which Deep TMS is not FDA-cleared, requiring additional controlled trials before any commercial pathway. The filing is a routine scientific update with no financial data, no regulatory submission, and no change to the company's existing three FDA-cleared indications, making it a modest positive signal for the platform's optionality but not a near-term catalyst.